Compare Deutsche Bank AG (DB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Summit Therapeutics Inc — how do they compare? Deutsche Bank AG trades at $38.21 (market cap $71.96B), while Summit Therapeutics Inc trades at $15.05 (market cap $12.06B). The key difference: Deutsche Bank AG is far larger — about 6× Summit Therapeutics Inc's market cap, and Deutsche Bank AG pays a 3.04% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DB | SMMT | |
|---|---|---|
Market Cap | $71.96B | $12.06B |
Sector | Financials | Health |
52-Week High | $40.33 | $26.98 |
52-Week Low | $28.37 | $12.55 |
Dividend Yield | 3.04% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $13.96, up 3.1% today, but faces bearish technical signals with negative ROE of -192.5% and net income of -$1.08B for 2025. The company's key catalyst is the FDA review of ivonescimab with a November 2026 decision, supported by expanded clinical trials in bladder and kidney cancer. Cash flow remains dependent on financing activities, with operating cash flow negative at -$323M in 2025.
Investment outlook hinges on ivonescimab's FDA approval, with analyst consensus target at $27.90 offering significant upside. However, high execution risk, ongoing losses, and fiduciary investigations present substantial downside. The stock represents a high-risk biotech speculation with binary outcomes based on regulatory success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
